Most Accessed Articles
Immunomodulatory Drugs (IMiDs) in Multiple Myeloma
, 2017; 17(9): 846-857.Shahzad Raza, Rachael A. Safyan and Suzanne Lentzsch*
DOI: 10.2174/1568009617666170214104426
Multiple Myeloma and the Immune Microenvironment
, 2017; 17(9): 806-818.Yawara Kawano, Aldo. M. Roccaro, Irene M. Ghobrial* and Jamil Azzi*
DOI: 10.2174/1568009617666170214102301
HR+, HER2– Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles
, 2017; 17(7): 637-649.Sarah L. Sammons, Donna L. Topping and Kimberly L. Blackwell*
DOI: 10.2174/1568009617666170330120452
Potential Anti-cancer Drugs Commonly Used for Other Indications
, 2015; 15(1): 35-52.Veronika Hanusova, Lenka Skalova, Vera Kralova and Petra Matouskova
DOI: 10.2174/1568009615666141229152812
Multimodal HDAC Inhibitors with Improved Anticancer Activity
, 2018; 18(1): 39-56.Rainer Schobert and Bernhard Biersack*
DOI: 10.2174/1568009617666170206102613
P-glycoprotein Inhibition as a Therapeutic Approach for Overcoming Multidrug Resistance in Cancer: Current Status and Future Perspectives
, 2013; 13(3): 326-346.Ziyad Binkhathlan and Afsaneh Lavasanifar
DOI: 10.2174/15680096113139990076
Electrochemotherapy as First Line Cancer Treatment: Experiences from Veterinary Medicine in Developing Novel Protocols
, 2016; 16(1): 43-52.E. P. Spugnini, T. Azzarito, S. Fais, M. Fanciulli and A. Baldi
DOI: 10.2174/156800961601151218155340
Webmaster Contact: info@benthamscience.org